Synonym
LY 163443; LY163443; LY-163443.
IUPAC/Chemical Name
Ethanone, 1-(2-hydroxy-3-propyl-4-((4-(1H-tetrazol-5-ylmethyl)phenoxy)methyl)phenyl)-
InChi Key
OKLGLROKXFUYEI-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H22N4O3/c1-3-4-18-15(7-10-17(13(2)25)20(18)26)12-27-16-8-5-14(6-9-16)11-19-21-23-24-22-19/h5-10,26H,3-4,11-12H2,1-2H3,(H,21,22,23,24)
SMILES Code
CC(C1=CC=C(COC2=CC=C(CC3=NN=NN3)C=C2)C(CCC)=C1O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
366.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lawrence JW, Kroll DJ, Eacho PI. Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus. J Lipid Res. 2000 Sep;41(9):1390-401. PubMed PMID: 10974046.
2: Nuessler V, Pelka-Fleischer R, Zwierzina H, Wilmanns W, Denzlinger C. Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64. PubMed PMID: 9110922.
3: Eacho PI, Foxworthy PS, Lawrence JW, Herron DK, Noonan DJ. Common structural requirements for peroxisome proliferation by tetrazole and carboxylic acid-containing compounds. Ann N Y Acad Sci. 1996 Dec 27;804:387-402. PubMed PMID: 8993558.
4: Dillard RD, Hahn RA, McCullough D, Carr FP, Rinkema LE, Roman CR, Fleisch JH. (Phenylmethoxy)phenyl derivatives of omega-oxo- and omega-tetrazolylalkanoic acids and related tetrazoles. Synthesis and evaluation as leukotriene D4 receptor antagonists. J Med Chem. 1991 Sep;34(9):2768-78. PubMed PMID: 1654427.
5: Denzlinger C, Grimberg M, Kapp A, Haberl C, Wilmanns W. Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70. Erratum in: Br J Pharmacol 1991 Jul;103(3):1834. PubMed PMID: 1855116; PubMed Central PMCID: PMC1917974.
6: Tracey WR, Bend JR, Hamilton JT, Paterson NA. Role of lipoxygenase, cyclooxygenase and cytochrome P-450 metabolites in contractions of isolated guinea pig pulmonary venules induced by hypoxia and anoxia. J Pharmacol Exp Ther. 1989 Sep;250(3):1097-104. PubMed PMID: 2506335.
7: Bitterman H, Lefer AM. Use of a novel peptide leukotriene receptor antagonist, Ly-163443, in splanchnic artery occlusion shock. Prostaglandins Leukot Essent Fatty Acids. 1988 May;32(2):63-70. PubMed PMID: 3406041.
8: Fleisch JH, Cloud ML, Marshall WS. A brief review of preclinical and clinical studies with LY171883 and some comments on newer cysteinyl leukotriene receptor antagonists. Ann N Y Acad Sci. 1988;524:356-68. Review. PubMed PMID: 2837970.
9: Dillard RD, Carr FP, McCullough D, Haisch KD, Rinkema LE, Fleisch JH. Leukotriene receptor antagonists. 2. The [[(tetrazol-5-ylaryl)oxy]methyl]acetophenone derivatives. J Med Chem. 1987 May;30(5):911-8. PubMed PMID: 3033245.
10: Fleisch JH, Rinkema LE, Haisch KD, McCullough D, Carr FP, Dillard RD. Evaluation of LY163443, 1-[2-hydroxy-3-propyl-4-([4- (1H-tetrazol-5-ylmethyl)phenoxy]methyl) phenyl]ethanone, as a pharmacologic antagonist of leukotrienes D4 and E4. Naunyn Schmiedebergs Arch Pharmacol. 1986 May;333(1):70-7. PubMed PMID: 3016562.
